BARBARA RAY: Open Payments
NPI 1225095243 · GAFFNEY, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 30 payments from 12 companies in 2025. Trend: 2023 $816 · 2024 $797 · 2025 $754
Food & beverage: $754
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $213 |
| Axsome Therapeutics, Inc. | 3 | $189 |
| Novo Nordisk Inc | 5 | $75 |
| PFIZER INC. | 4 | $72 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Lilly USA, LLC | 2 | $41 |
| Ardelyx, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: Symbravo, FARXIGA, BREZTRI, NURTEC ODT, TRELEGY ELLIPTA, Rybelsus, REXULTI, Ozempic.
Industry payments across SC — which companies pay providers there.
